

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	26	24.5	106.2	(69.4-155.6)	Male	8	12.2	65.4	(28.2-128.9)
Female	4	9.1	nc	(nc-nc)	Female	2	9.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	4.6	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	2	0.7	nc	(nc-nc)	Male	11	12.2	90.4	(45.1-161.8)
Female	99	86.1	115.0	(93.5-140.0)	Female	9	11.0	81.6	(37.2-154.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	3.9	nc	(nc-nc)	Male	7	8.8	79.4	(31.8-163.6)
Colon / Rectum					Female	7	4.3	162.0	(64.9-333.8)
Male	37	37.5	98.6	(69.4-135.9)	Ovary				
Female	34	38.1	89.3	(61.8-124.8)	Female	13	9.0	144.9	(77.1-247.8)
Esophagus					Pancreas				
Male	4	5.7	nc	(nc-nc)	Male	7	6.9	101.0	(40.5-208.1)
Female	1	1.9	nc	(nc-nc)	Female	10	8.0	125.8	(60.2-231.3)
Hodgkin Lymphoma					Prostate				
Male	0	2.1	nc	(nc-nc)	Male	92	95.1	96.7	(78.0-118.6)
Female	0	1.6	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	4	6.4	nc	(nc-nc)
Male	11	9.4	117.4	(58.5-210.1)	Female	2	4.1	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	Testis				
Larynx					Male	2	3.7	nc	(nc-nc)
Male	8	4.2	190.5	(82.0-375.4)					

Female	0	1.1	nc	(nc-nc)
Leukemia				
Male	7	7.5	93.8	(37.6-193.3)
Female	3	6.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	4.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)
Lung and Bronchus				
Male	49	47.2	103.9	(76.9-137.4)
Female	36	40.5	88.8	(62.2-123.0)

#### Thyroid

Male	1	2.3	nc	(nc-nc)
Female	8	6.5	122.9	(52.9-242.2)

#### Uteri Corpus and Uterus, NOS

Female	16	16.8	95.4	(54.5-155.0)
--------	----	------	------	--------------

#### All Sites / Types

Male	306	320.2	95.6	(85.1-106.9)
Female	280	294.5	95.1	(84.3-106.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

### 115 Georgetown

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	6.4	nc	(nc-nc)	Male	6	3.7	161.0	(58.8-350.4)
Female	1	2.2	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	6	3.6	168.2	(61.4-366.0)
Female	32	27.8	115.2	(78.8-162.7)	Female	5	2.9	170.1	(54.8-397.0)
Cervix Uteri					Oral Cavity & Pharynx				

Colon / Rectum	Female	1	1.4	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
	Male	13	10.1	128.6	(68.4-220.0)	Female	2	1.2	nc	(nc-nc)
Esophagus	Female	9	8.8	102.4	(46.7-194.4)	Female	2	2.7	nc	(nc-nc)
	Male	2	1.7	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
	Male	1	0.6	nc	(nc-nc)	Male	22	28.1	78.2	(49.0-118.4)
Kidney & Renal Pelvis	Female	0	0.5	nc	(nc-nc)	Prostate				
	Male	3	2.9	nc	(nc-nc)	Stomach				
Larynx	Female	0	1.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
	Male	0	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Leukemia	Female	0	0.3	nc	(nc-nc)	Testis				
	Male	1	2.2	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	1.7	nc	(nc-nc)	Thyroid				
	Male	0	1.4	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Lung and Bronchus	Female	0	0.4	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
	Male	20	12.9	154.9	(94.6-239.3)	Uteri Corpus and Uterus, NOS				
	Female	11	10.6	103.9	(51.8-185.9)	Female	5	5.3	93.9	(30.3-219.1)
						All Sites / Types				
	Male	98	91.9	106.6	(86.5-129.9)	Male	98	91.9	106.6	(86.5-129.9)
	Female	85	83.8	101.4	(81.0-125.4)	Female	85	83.8	101.4	(81.0-125.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

116

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	1.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	7	6.3	111.2	(44.5-229.0)	Female	1	0.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	2	2.5	nc	(nc-nc)					
Female	2	2.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	6	6.4	93.2	(34.0-202.9)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	1	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)

Larynx	Female	0	0.4	nc	(nc-nc)	Testis	Female	1	0.2	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
Leukemia	Female	0	0.1	nc	(nc-nc)	Thyroid					
	Male	0	0.5	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.3	nc	(nc-nc)						
	Female	0	0.1	nc	(nc-nc)		Female	0	1.2	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	2	3.1	nc	(nc-nc)		Male	20	21.5	93.1	(56.9-143.9)
	Female	4	2.5	nc	(nc-nc)		Female	17	19.3	87.9	(51.2-140.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

117  
Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	38	34.9	109.0	(77.1-149.6)	Male	13	17.7	73.5	(39.1-125.7)
Female	16	13.6	118.0	(67.4-191.6)	Female	12	14.4	83.3	(43.0-145.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	6.6	nc	(nc-nc)	Male	5	4.9	102.5	(33.0-239.3)
Female	8	5.8	138.7	(59.7-273.3)	Female	8	4.2	188.7	(81.2-371.8)
Breast					Non-Hodgkin Lymphoma				

Male	0	1.1	nc	(nc-nc)
Female	143	138.8	103.0	(86.8-121.3)
Cervix Uteri				
Female	10	6.3	159.8	(76.5-293.9)
Colon / Rectum				
Male	46	53.8	85.4	(62.5-114.0)
Female	56	55.3	101.3	(76.5-131.5)
Esophagus				
Male	11	8.5	129.1	(64.3-231.0)
Female	1	2.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	2.8	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	14	13.9	100.5	(54.9-168.6)
Female	9	9.6	94.1	(42.9-178.6)
Larynx				
Male	10	6.3	158.2	(75.7-291.0)
Female	1	1.7	nc	(nc-nc)
Leukemia				
Male	15	10.5	142.2	(79.6-234.6)
Female	9	9.2	97.7	(44.6-185.5)
Liver and Intrahepatic Bile Ducts				
Male	7	6.5	107.8	(43.2-222.2)
Female	3	2.6	nc	(nc-nc)
Lung and Bronchus				
Male	70	68.7	101.9	(79.4-128.7)
Female	65	62.3	104.4	(80.5-133.0)

Male	20	17.4	115.0	(70.2-177.5)
Female	18	16.6	108.2	(64.1-170.9)
Oral Cavity & Pharynx				
Male	21	13.4	156.9	(97.1-239.9)
Female	6	6.8	88.9	(32.4-193.4)
Ovary				
Female	16	14.2	112.8	(64.4-183.2)
Pancreas				
Male	16	10.0	159.7	(91.2-259.4)
Female	11	11.5	95.4	(47.6-170.8)
Prostate				
Male	128	143.9	88.9	(74.2-105.8)
Stomach				
Male	10	9.1	109.5	(52.4-201.3)
Female	9	5.9	153.2	(69.9-290.8)
Testis				
Male	6	4.7	128.7	(47.0-280.2)
Thyroid				
Male	6	3.3	180.9	(66.1-393.8)
Female	10	10.6	94.8	(45.4-174.3)
Uteri Corpus and Uterus, NOS				
Female	27	27.4	98.4	(64.8-143.2)
All Sites / Types				
Male	486	468.1	103.8	(94.8-113.5)
Female	468	455.1	102.8	(93.7-112.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

118  
Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	1.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.2	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Colon / Rectum					Female	0	0.2	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Ovary				
Female	0	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	6	4.4	137.0	(50.0-298.2)
Female	0	0.1	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach				
	Male	2	0.4	nc	(nc-nc)		Male	0	0.3	nc (nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Larynx						Testis				
	Male	0	0.2	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.3	nc	(nc-nc)		Male	1	0.1	nc (nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	1	0.3	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.2	nc	(nc-nc)					
	Female	0	0.1	nc	(nc-nc)		Female	1	0.8	nc (nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	1	2.1	nc	(nc-nc)		Male	13	14.1	92.4 (49.2-158.1)
	Female	2	1.5	nc	(nc-nc)		Female	7	12.1	58.1 (23.3-119.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

119  
Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
	Male	1	0.2	nc (nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.0	nc (nc-nc)		Female	0	0.0	nc (nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
	Male	0	0.0	nc (nc-nc)		Male	0	0.0	nc (nc-nc)



Breast	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Cervix Uteri	Female	0	0.4	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Colon / Rectum	Female	0	0.0	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)
Esophagus	Female	0	0.2	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	0.0	nc	(nc-nc)
	Male	1	0.1	nc	(nc-nc)
Larynx	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Leukemia	Female	0	0.0	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Lung and Bronchus	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)

Non-Hodgkin Lymphoma	Female	0	0.0	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)
Oral Cavity & Pharynx	Female	0	0.0	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)
Ovary	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Pancreas	Female	0	0.0	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)
Prostate	Female	0	0.0	nc	(nc-nc)
	Male	0	0.8	nc	(nc-nc)
Stomach	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Testis	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Thyroid	Female	0	0.0	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	0	0.1	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)
All Sites / Types	Female	0	0.1	nc	(nc-nc)
	Male	0	0.0	nc	(nc-nc)

Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Male	2	2.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

120  
Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	8	13.7	58.2	(25.1-114.7)	Male	5	7.4	67.1	(21.6-156.7)
Female	6	5.1	118.8	(43.4-258.5)	Female	4	6.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	2.9	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	5	1.6	314.0	(101.2-732.8)
Breast					Non-Hodgkin Lymphoma				
Male	2	0.4	nc	(nc-nc)	Male	7	7.3	96.1	(38.5-198.0)
Female	86	56.9	151.1	(120.9-186.7)	Female	9	6.6	136.9	(62.5-259.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	2.9	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Colon / Rectum					Female	3	2.7	nc	(nc-nc)
Male	15	21.4	70.1	(39.2-115.7)	Ovary				
Female	17	20.4	83.3	(48.5-133.5)	Female	4	5.8	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	3.4	nc	(nc-nc)	Male	5	4.0	125.2	(40.3-292.1)
Female	1	1.0	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)

Hodgkin Lymphoma					Prostate				
Male	0	1.3	nc	(nc-nc)	Male	42	56.8	73.9	(53.3-99.9)
Female	0	1.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	3	5.8	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
Larynx					Testis				
Male	1	2.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	3	4.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	3	2.7	nc	(nc-nc)					
Female	0	1.0	nc	(nc-nc)	Female	11	11.1	99.1	(49.4-177.3)
Lung and Bronchus					All Sites / Types				
Male	23	27.2	84.5	(53.5-126.7)	Male	141	188.8	74.7	(62.9-88.1)
Female	27	23.9	112.7	(74.3-164.0)	Female	195	180.9	107.8	(93.2-124.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

121  
Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	6.1	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)

Brain and Other Nervous System	Female	0	2.1	nc	(nc-nc)	Multiple Myeloma	Female	2	2.6	nc	(nc-nc)
	Male	1	1.3	nc	(nc-nc)		Male	0	0.9	nc	(nc-nc)
	Female	1	1.0	nc	(nc-nc)		Female	1	0.6	nc	(nc-nc)
Breast	Male	1	0.2	nc	(nc-nc)	Non-Hodgkin Lymphoma	Male	3	3.2	nc	(nc-nc)
	Female	26	24.1	108.0	(70.5-158.2)		Female	0	2.7	nc	(nc-nc)
Cervix Uteri	Male					Oral Cavity & Pharynx	Male	6	2.5	236.3	(86.3-514.3)
	Female	0	1.2	nc	(nc-nc)		Female	0	1.1	nc	(nc-nc)
Colon / Rectum	Male	7	9.5	73.8	(29.6-152.0)	Ovary					
	Female	7	8.1	86.4	(34.6-177.9)		Female	0	2.4	nc	(nc-nc)
Esophagus	Male	1	1.6	nc	(nc-nc)	Pancreas	Male	2	1.8	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	1	1.7	nc	(nc-nc)
Hodgkin Lymphoma	Male	1	0.6	nc	(nc-nc)	Prostate	Male	21	26.3	79.9	(49.5-122.2)
	Female	0	0.5	nc	(nc-nc)						
Kidney & Renal Pelvis	Male	3	2.6	nc	(nc-nc)	Stomach	Male	1	1.6	nc	(nc-nc)
	Female	0	1.6	nc	(nc-nc)		Female	1	0.8	nc	(nc-nc)
Larynx	Male	2	1.2	nc	(nc-nc)	Testis	Male	2	0.9	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)						
Leukemia	Male	2	1.9	nc	(nc-nc)	Thyroid	Male	2	0.7	nc	(nc-nc)
	Female	2	1.5	nc	(nc-nc)		Female	2	2.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					

Male	0	1.2	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	6	4.7	126.6	(46.2-275.6)
Lung and Bronchus					All Sites / Types				
Male	13	12.3	106.0	(56.4-181.3)	Male	76	84.8	89.6	(70.6-112.2)
Female	7	9.9	70.4	(28.2-145.0)	Female	62	74.8	82.9	(63.6-106.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

122  
Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	7	5.9	117.7	(47.2-242.5)	Female	0	0.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
					Female	0	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	2	2.3	nc	(nc-nc)					
Female	2	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)

Esophagus						Pancreas				
Male	0	0.4	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.1	nc	(nc-nc)		Male	6	6.3	95.1	(34.7-207.1)
Female	0	0.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	0	0.6	nc	(nc-nc)		Male	2	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Larynx						Testis				
Male	0	0.3	nc	(nc-nc)		Male	3	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)						
Leukemia						Thyroid				
Male	0	0.5	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)		Female	1	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	0.3	nc	(nc-nc)						
Female	0	0.1	nc	(nc-nc)		Female	0	1.2	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	3	2.9	nc	(nc-nc)		Male	23	20.4	112.5	(71.3-168.9)
Female	3	2.4	nc	(nc-nc)		Female	16	18.2	88.0	(50.3-143.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	9.6	73.0	(29.2-150.3)
Female	4	4.1	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)
Breast				
Male	1	0.3	nc	(nc-nc)
Female	30	38.9	77.1	(52.0-110.0)
Cervix Uteri				
Female	0	1.6	nc	(nc-nc)
Colon / Rectum				
Male	13	14.7	88.5	(47.1-151.4)
Female	16	17.2	92.8	(53.0-150.7)
Esophagus				
Male	1	2.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	3.6	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)
Larynx				
Male	2	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Leukemia				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	4.6	172.6	(74.3-340.2)
Female	4	3.9	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	4.6	172.7	(74.4-340.3)
Female	3	4.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	5	3.5	143.6	(46.3-335.0)
Female	1	1.9	nc	(nc-nc)
Ovary				
Female	4	4.0	nc	(nc-nc)
Pancreas				
Male	5	2.7	183.2	(59.0-427.5)
Female	3	3.6	nc	(nc-nc)
Prostate				
Male	44	37.3	118.0	(85.7-158.4)
Stomach				
Male	1	2.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)
Testis				
Male	1	1.1	nc	(nc-nc)
Thyroid				

Male	0	2.8	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Lung and Bronchus				
Male	18	18.4	98.0	(58.1-154.9)
Female	20	18.0	111.1	(67.9-171.6)

Male	0	0.8	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	7	7.6	91.8	(36.8-189.1)
All Sites / Types				
Male	129	124.2	103.9	(86.7-123.5)
Female	120	131.8	91.0	(75.5-108.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

124  
Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	16	21.5	74.4	(42.5-120.9)
Female	13	9.3	139.9	(74.4-239.3)
Brain and Other Nervous System				
Male	5	3.8	131.0	(42.2-305.7)
Female	4	3.7	nc	(nc-nc)
Breast				
Male	0	0.6	nc	(nc-nc)
Female	81	86.2	94.0	(74.6-116.8)
Cervix Uteri				
Female	9	3.8	238.4	(108.8-452.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	10.4	nc	(nc-nc)
Female	7	9.0	77.9	(31.2-160.6)
Multiple Myeloma				
Male	3	3.0	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	10.4	76.6	(33.0-151.0)
Female	14	11.1	126.1	(68.9-211.6)
Oral Cavity & Pharynx				
Male	4	7.6	nc	(nc-nc)
Female	2	4.3	nc	(nc-nc)



Colon / Rectum						Ovary				
Male	24	32.8	73.2	(46.9-108.9)						
Female	42	39.5	106.4	(76.6-143.8)		Female	10	9.0	111.0	(53.1-204.1)
Esophagus						Pancreas				
Male	1	4.9	nc	(nc-nc)		Male	7	6.1	115.4	(46.2-237.7)
Female	1	1.9	nc	(nc-nc)		Female	7	8.2	85.4	(34.2-176.0)
Hodgkin Lymphoma						Prostate				
Male	0	1.6	nc	(nc-nc)		Male	70	80.9	86.5	(67.4-109.3)
Female	4	1.5	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	4	8.1	nc	(nc-nc)		Male	3	5.6	nc	(nc-nc)
Female	4	6.1	nc	(nc-nc)		Female	0	4.3	nc	(nc-nc)
Larynx						Testis				
Male	1	3.6	nc	(nc-nc)		Male	3	2.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)						
Leukemia						Thyroid				
Male	3	6.4	nc	(nc-nc)		Male	0	1.8	nc	(nc-nc)
Female	7	6.3	111.7	(44.8-230.2)		Female	5	6.3	79.8	(25.7-186.2)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	6	3.8	158.3	(57.8-344.5)						
Female	1	1.8	nc	(nc-nc)		Female	19	16.5	115.1	(69.3-179.8)
Lung and Bronchus						All Sites / Types				
Male	40	40.9	97.7	(69.8-133.1)		Male	222	275.4	80.6	(70.3-91.9)
Female	47	40.1	117.1	(86.0-155.8)		Female	305	296.2	103.0	(91.7-115.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



Male	0	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)					
Leukemia					Thyroid				
Male	2	2.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	1.5	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)	Female	5	5.9	84.4	(27.2-196.9)
Lung and Bronchus					All Sites / Types				
Male	11	13.8	79.7	(39.7-142.6)	Male	98	99.9	98.1	(79.7-119.6)
Female	6	11.2	53.6	(19.6-116.7)	Female	84	92.8	90.5	(72.2-112.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

126  
Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	10	5.4	185.9	(89.0-342.0)	Male	2	3.0	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	6	2.9	204.4	(74.6-444.9)
Female	23	22.6	101.6	(64.4-152.4)	Female	1	2.4	nc	(nc-nc)

Cervix Uteri						Oral Cavity & Pharynx					
	Male	0	2.4	nc	(nc-nc)		Male	0	2.4	nc	(nc-nc)
	Female	1	1.1	nc	(nc-nc)		Female	0	1.0	nc	(nc-nc)
Colon / Rectum						Ovary					
	Male	12	8.4	142.0	(73.3-248.1)						
	Female	10	7.3	136.5	(65.3-251.0)		Female	5	2.2	222.5	(71.7-519.2)
Esophagus						Pancreas					
	Male	0	1.4	nc	(nc-nc)		Male	1	1.6	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	0	1.5	nc	(nc-nc)
Hodgkin Lymphoma						Prostate					
	Male	0	0.5	nc	(nc-nc)		Male	22	23.5	93.5	(58.6-141.5)
	Female	1	0.4	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach					
	Male	2	2.4	nc	(nc-nc)		Male	4	1.4	nc	(nc-nc)
	Female	1	1.4	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Larynx						Testis					
	Male	3	1.1	nc	(nc-nc)		Male	0	0.9	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	2	1.8	nc	(nc-nc)		Male	2	0.6	nc	(nc-nc)
	Female	0	1.4	nc	(nc-nc)		Female	2	2.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	1.1	nc	(nc-nc)						
	Female	0	0.4	nc	(nc-nc)		Female	7	4.4	160.0	(64.1-329.7)
Lung and Bronchus						All Sites / Types					
	Male	11	10.9	100.6	(50.1-180.0)		Male	85	76.5	111.2	(88.8-137.5)
	Female	14	8.9	157.6	(86.1-264.5)		Female	73	69.0	105.8	(82.9-133.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

127  
Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	6.6	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	1.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	25	23.9	104.7	(67.8-154.6)	Female	7	3.0	233.2	(93.4-480.5)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	1.0	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Colon / Rectum					Female	0	1.2	nc	(nc-nc)
Male	7	10.0	69.9	(28.0-144.1)	Ovary				
Female	10	10.5	95.4	(45.7-175.5)	Female	1	2.5	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	1.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	2	0.4	nc	(nc-nc)	Male	26	24.5	106.2	(69.4-155.6)
Female	0	0.4	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach				
Male	2	2.4	nc	(nc-nc)		Male	3	1.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)		Female	2	1.1	nc	(nc-nc)
Larynx						Testis				
Male	0	1.1	nc	(nc-nc)		Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)						
Leukemia						Thyroid				
Male	2	1.9	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)		Female	3	1.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	1	1.1	nc	(nc-nc)						
Female	1	0.5	nc	(nc-nc)		Female	2	4.6	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	7	12.5	55.9	(22.4-115.3)		Male	77	83.2	92.6	(73.1-115.7)
Female	6	11.1	54.1	(19.7-117.7)		Female	74	80.6	91.8	(72.1-115.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

128  
Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	9	7.6	118.8	(54.2-225.6)	Male	4	4.0	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	5	3.3	150.3	(48.4-350.7)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)

Breast	Female	1	1.3	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Cervix Uteri	Female	32	31.5	101.7	(69.5-143.5)
Colon / Rectum	Female	2	1.5	nc	(nc-nc)
	Male	16	11.8	135.9	(77.7-220.8)
Esophagus	Female	11	11.6	95.2	(47.4-170.3)
	Male	1	1.9	nc	(nc-nc)
Hodgkin Lymphoma	Female	1	0.6	nc	(nc-nc)
	Male	1	0.7	nc	(nc-nc)
Kidney & Renal Pelvis	Female	1	0.6	nc	(nc-nc)
	Male	5	3.1	159.4	(51.4-372.0)
Larynx	Female	6	2.1	285.3	(104.2-620.9)
	Male	3	1.4	nc	(nc-nc)
Leukemia	Female	1	0.4	nc	(nc-nc)
	Male	5	2.4	209.5	(67.5-488.9)
Liver and Intrahepatic Bile Ducts	Female	3	2.0	nc	(nc-nc)
	Male	0	1.4	nc	(nc-nc)
Lung and Bronchus	Female	1	0.6	nc	(nc-nc)

Non-Hodgkin Lymphoma	Female	2	0.9	nc	(nc-nc)
	Male	3	3.9	nc	(nc-nc)
Oral Cavity & Pharynx	Female	5	3.6	137.5	(44.3-320.9)
	Male	3	3.1	nc	(nc-nc)
Ovary	Female	0	1.5	nc	(nc-nc)
Pancreas	Female	5	3.2	156.9	(50.6-366.3)
	Male	5	2.2	226.8	(73.1-529.3)
Prostate	Female	3	2.4	nc	(nc-nc)
	Male	27	31.8	85.0	(56.0-123.6)
Stomach	Male	3	2.0	nc	(nc-nc)
	Female	2	1.2	nc	(nc-nc)
Testis	Male	0	1.1	nc	(nc-nc)
Thyroid	Male	0	0.8	nc	(nc-nc)
	Female	0	2.6	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					
	Female	8	6.2	129.0	(55.6-254.2)
All Sites / Types					

Male	18	15.0	120.4	(71.3-190.3)
Female	16	13.5	118.8	(67.9-193.0)

Male	111	103.7	107.1	(88.1-129.0)
Female	114	100.4	113.5	(93.7-136.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

129  
Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	7.9	88.1	(35.3-181.6)	Male	6	4.3	138.2	(50.5-300.8)
Female	1	2.6	nc	(nc-nc)	Female	6	3.4	177.3	(64.7-385.9)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)	Male	5	4.2	118.4	(38.1-276.2)
Female	32	31.3	102.1	(69.8-144.2)	Female	3	3.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	1.6	nc	(nc-nc)	Male	6	3.3	181.2	(66.2-394.5)
Colon / Rectum					Female	0	1.4	nc	(nc-nc)
Male	11	12.4	88.7	(44.2-158.7)	Ovary				
Female	14	10.2	136.9	(74.8-229.7)	Female	2	3.1	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	2.0	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	5	2.1	237.0	(76.4-553.0)



Hodgkin Lymphoma						Prostate				
Male	0	0.8	nc	(nc-nc)		Male	27	33.7	80.2	(52.8-116.7)
Female	2	0.6	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	3	3.4	nc	(nc-nc)		Male	1	2.1	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)		Female	0	1.1	nc	(nc-nc)
Larynx						Testis				
Male	0	1.5	nc	(nc-nc)		Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)						
Leukemia						Thyroid				
Male	3	2.6	nc	(nc-nc)		Male	1	0.9	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)		Female	2	2.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	1	1.6	nc	(nc-nc)						
Female	0	0.5	nc	(nc-nc)		Female	4	6.1	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	6	15.9	37.8	(13.8-82.2)		Male	92	110.4	83.3	(67.2-102.2)
Female	7	12.6	55.7	(22.3-114.8)		Female	93	96.3	96.6	(77.9-118.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

130  
Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	5.4	128.6	(51.5-264.9)	Male	2	2.9	nc	(nc-nc)

Brain and Other Nervous System	Female	2	2.0	nc	(nc-nc)
	Male	1	1.1	nc	(nc-nc)
	Female	2	0.9	nc	(nc-nc)
Breast	Male	0	0.2	nc	(nc-nc)
	Female	27	22.2	121.9	(80.3-177.3)
Cervix Uteri	Female	2	1.0	nc	(nc-nc)
	Male	7	8.5	82.4	(33.0-169.8)
	Female	5	7.9	63.1	(20.3-147.3)
Esophagus	Male	1	1.4	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma	Male	0	0.4	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis	Male	2	2.3	nc	(nc-nc)
	Female	0	1.4	nc	(nc-nc)
Larynx	Male	0	1.1	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)
Leukemia	Male	1	1.7	nc	(nc-nc)
	Female	0	1.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					

Multiple Myeloma	Female	3	2.3	nc	(nc-nc)
	Male	1	0.8	nc	(nc-nc)
	Female	0	0.6	nc	(nc-nc)
Non-Hodgkin Lymphoma	Male	3	2.8	nc	(nc-nc)
	Female	1	2.4	nc	(nc-nc)
Oral Cavity & Pharynx	Male	2	2.3	nc	(nc-nc)
	Female	1	1.0	nc	(nc-nc)
Ovary	Female	1	2.2	nc	(nc-nc)
	Male	1	1.6	nc	(nc-nc)
	Female	1	1.6	nc	(nc-nc)
Pancreas	Male	1	1.6	nc	(nc-nc)
	Female	1	1.6	nc	(nc-nc)
Prostate	Male	28	23.5	118.9	(79.0-171.9)
Stomach	Male	2	1.4	nc	(nc-nc)
	Female	0	0.8	nc	(nc-nc)
Testis	Male	1	0.7	nc	(nc-nc)
Thyroid	Male	0	0.6	nc	(nc-nc)
	Female	3	1.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					

Male	0	1.1	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)	Female	1	4.4	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	7	10.9	64.1	(25.7-132.2)	Male	70	75.5	92.7	(72.3-117.2)
Female	16	9.0	176.8	(101.0-287.2)	Female	66	69.3	95.3	(73.7-121.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

131  
Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	1	1.4	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)

Esophagus						Pancreas					
	Male	0	0.2	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma						Prostate					
	Male	0	0.1	nc	(nc-nc)		Male	2	3.9	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach					
	Male	2	0.4	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Larynx						Testis					
	Male	0	0.2	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	0	0.3	nc	(nc-nc)		Male	0	0.1	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.2	nc	(nc-nc)						
	Female	0	0.1	nc	(nc-nc)		Female	1	0.7	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	1	1.8	nc	(nc-nc)		Male	8	12.2	65.8	(28.3-129.7)
	Female	3	1.3	nc	(nc-nc)		Female	9	9.9	91.2	(41.6-173.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	8	11.3	70.8	(30.5-139.5)
Female	5	4.4	112.5	(36.3-262.6)
Brain and Other Nervous System				
Male	2	2.6	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	61	52.8	115.4	(88.3-148.3)
Cervix Uteri				
Female	2	2.5	nc	(nc-nc)
Colon / Rectum				
Male	22	17.9	122.9	(77.0-186.0)
Female	21	17.7	118.3	(73.2-180.9)
Esophagus				
Male	2	3.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	5	5.1	97.2	(31.3-226.8)
Female	5	3.4	147.2	(47.4-343.5)
Larynx				
Male	1	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	6.5	153.3	(73.4-282.0)
Female	7	5.5	126.6	(50.7-260.9)
Multiple Myeloma				
Male	2	1.7	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	6.3	nc	(nc-nc)
Female	7	5.8	121.6	(48.7-250.5)
Oral Cavity & Pharynx				
Male	7	5.2	135.3	(54.2-278.7)
Female	3	2.4	nc	(nc-nc)
Ovary				
Female	5	5.3	94.8	(30.5-221.1)
Pancreas				
Male	2	3.4	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)
Prostate				
Male	55	50.7	108.4	(81.6-141.1)
Stomach				
Male	1	3.0	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)
Testis				
Male	3	2.0	nc	(nc-nc)
Thyroid				

Male	1	3.8	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	2.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Lung and Bronchus				
Male	22	23.0	95.5	(59.8-144.5)
Female	21	21.2	98.8	(61.2-151.1)

Male	0	1.4	nc	(nc-nc)
Female	7	4.4	158.3	(63.4-326.1)
Uteri Corpus and Uterus, NOS				
Female	11	10.4	105.7	(52.7-189.1)
All Sites / Types				
Male	155	163.5	94.8	(80.5-111.0)
Female	182	162.8	111.8	(96.1-129.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

133

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	12	7.9	152.2	(78.6-265.9)
Female	2	2.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	1.8	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	42	34.5	121.7	(87.7-164.5)
Cervix Uteri				
Female	0	1.7	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	4.6	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)
Multiple Myeloma				
Male	3	1.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	3	4.4	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	6	3.6	166.6	(60.8-362.6)
Female	2	1.6	nc	(nc-nc)

Colon / Rectum						Ovary				
Male	25	12.5	200.4	(129.6-295.8)						
Female	11	10.9	100.6	(50.1-180.0)		Female	2	3.4	nc	(nc-nc)
Esophagus						Pancreas				
Male	4	2.1	nc	(nc-nc)		Male	1	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)		Female	2	2.2	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.8	nc	(nc-nc)		Male	27	35.2	76.8	(50.6-111.7)
Female	1	0.7	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	1	3.6	nc	(nc-nc)		Male	2	2.1	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)		Female	1	1.1	nc	(nc-nc)
Larynx						Testis				
Male	1	1.6	nc	(nc-nc)		Male	1	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)						
Leukemia						Thyroid				
Male	4	2.7	nc	(nc-nc)		Male	1	1.0	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)		Female	4	3.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	2	1.7	nc	(nc-nc)						
Female	0	0.5	nc	(nc-nc)		Female	10	6.8	147.8	(70.7-271.7)
Lung and Bronchus						All Sites / Types				
Male	25	16.1	155.7	(100.7-229.8)		Male	131	113.9	115.0	(96.1-136.5)
Female	21	13.3	157.5	(97.5-240.8)		Female	116	104.7	110.8	(91.5-132.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;





Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	0.9	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.5	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	9	5.6	161.8	(73.8-307.2)	Male	31	38.0	81.5	(55.4-115.7)
Female	5	4.8	104.7	(33.7-244.4)	Female	46	35.2	130.6	(95.6-174.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

135 Harvard Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	5.8	86.1	(27.7-200.8)	Male	6	3.9	153.3	(56.0-333.8)
Female	1	1.6	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.6	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.2	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
Female	21	23.4	89.7	(55.5-137.1)	Female	2	2.3	nc	(nc-nc)

Cervix Uteri					Oral Cavity & Pharynx				
	Male	4	3.0	nc	(nc-nc)				
	Female	0	1.3	nc	(nc-nc)				
Colon / Rectum					Ovary				
	Male	7	9.4	74.5	(29.9-153.6)				
	Female	6	6.2	97.3	(35.5-211.8)				
Esophagus					Pancreas				
	Male	1	1.6	nc	(nc-nc)				
	Female	0	0.3	nc	(nc-nc)				
Hodgkin Lymphoma					Prostate				
	Male	1	0.9	nc	(nc-nc)				
	Female	0	0.5	nc	(nc-nc)				
Kidney & Renal Pelvis					Stomach				
	Male	6	2.9	208.5	(76.1-453.9)				
	Female	1	1.4	nc	(nc-nc)				
Larynx					Testis				
	Male	1	1.3	nc	(nc-nc)				
	Female	0	0.3	nc	(nc-nc)				
Leukemia					Thyroid				
	Male	2	2.2	nc	(nc-nc)				
	Female	2	1.3	nc	(nc-nc)				
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
	Male	1	1.3	nc	(nc-nc)				
	Female	0	0.3	nc	(nc-nc)				
Lung and Bronchus					All Sites / Types				
	Male	8	11.8	67.6	(29.1-133.3)				
	Female	4	8.0	nc	(nc-nc)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

136

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	32	24.1	133.0	(90.9-187.7)	Male	19	10.1	188.8	(113.6-294.8)
Female	15	9.0	166.1	(92.9-273.9)	Female	12	7.5	159.9	(82.5-279.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	5	3.4	147.7	(47.6-344.8)	Male	4	3.2	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)	Male	12	10.4	115.9	(59.8-202.5)
Female	95	77.9	122.0	(98.7-149.1)	Female	12	10.4	115.6	(59.7-201.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	3.0	nc	(nc-nc)	Male	6	7.3	82.7	(30.2-180.1)
					Female	6	4.0	149.5	(54.6-325.4)
Colon / Rectum					Ovary				
Male	26	36.1	72.1	(47.1-105.6)					
Female	56	37.7	148.6	(112.2-193.0)	Female	8	8.2	98.0	(42.2-193.2)
Esophagus					Pancreas				
Male	6	5.3	113.8	(41.5-247.7)	Male	9	6.6	136.2	(62.1-258.5)
Female	0	1.8	nc	(nc-nc)	Female	7	7.9	88.2	(35.3-181.7)
Hodgkin Lymphoma					Prostate				
Male	0	1.1	nc	(nc-nc)	Male	132	89.3	147.9	(123.7-175.4)
Female	0	1.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

	Male	15	8.1	185.1	(103.5-305.2)
	Female	6	5.8	102.6	(37.5-223.3)
Larynx					
	Male	4	3.8	nc	(nc-nc)
	Female	1	1.0	nc	(nc-nc)
Leukemia					
	Male	7	6.4	109.4	(43.8-225.4)
	Female	7	5.6	124.3	(49.8-256.2)
Liver and Intrahepatic Bile Ducts					
	Male	3	3.8	nc	(nc-nc)
	Female	0	1.7	nc	(nc-nc)
Lung and Bronchus					
	Male	42	45.3	92.8	(66.9-125.4)
	Female	29	40.0	72.5	(48.5-104.1)

	Male	5	6.2	81.0	(26.1-189.0)
	Female	3	4.1	nc	(nc-nc)
Testis					
	Male	3	1.4	nc	(nc-nc)
Thyroid					
	Male	1	1.4	nc	(nc-nc)
	Female	4	4.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					
	Female	20	15.6	128.2	(78.3-198.0)
All Sites / Types					
	Male	354	293.3	120.7	(108.4-133.9)
	Female	302	274.4	110.1	(98.0-123.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

137  
Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	5	4.2	119.7	(38.6-279.2)
Female	2	1.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	2.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)		Male	2	2.1	nc	(nc-nc)
Female	17	15.7	108.1	(62.9-173.1)		Female	0	1.9	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
Female	1	0.7	nc	(nc-nc)		Male	6	1.6	372.8	(136.1-811.6)
						Female	0	0.7	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	3	6.4	nc	(nc-nc)						
Female	4	6.2	nc	(nc-nc)		Female	0	1.6	nc	(nc-nc)
Esophagus						Pancreas				
Male	1	1.0	nc	(nc-nc)		Male	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)		Female	3	1.3	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	2	0.3	nc	(nc-nc)		Male	16	17.0	94.3	(53.9-153.1)
Female	0	0.2	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	2	1.7	nc	(nc-nc)		Male	0	1.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)		Female	1	0.6	nc	(nc-nc)
Larynx						Testis				
Male	1	0.8	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)						
Leukemia						Thyroid				
Male	0	1.2	nc	(nc-nc)		Male	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)		Female	2	1.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	1	0.8	nc	(nc-nc)						
Female	0	0.3	nc	(nc-nc)		Female	4	3.1	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	9	8.2	109.4	(49.9-207.7)		Male	56	55.6	100.8	(76.1-130.9)

Female 5 7.0 71.4 (23.0-166.6)

Female 44 51.0 86.3 (62.7-115.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

138  
Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	44	52.6	83.7	(60.8-112.3)	Male	13	27.8	46.8	(24.9-80.0)
Female	17	22.3	76.2	(44.4-122.0)	Female	12	25.1	47.8	(24.7-83.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	9	11.0	82.2	(37.5-156.0)	Male	7	7.4	95.0	(38.1-195.8)
Female	10	10.2	98.4	(47.1-181.0)	Female	5	6.9	72.1	(23.2-168.3)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.6	nc	(nc-nc)	Male	20	27.4	73.0	(44.6-112.7)
Female	213	227.8	93.5	(81.4-106.9)	Female	33	28.0	118.1	(81.3-165.8)
Cervix Uteri					Oral Cavity & Pharynx				
Female	11	11.1	98.7	(49.2-176.6)	Male	19	20.2	94.0	(56.6-146.8)
Colon / Rectum					Female	11	11.1	98.7	(49.2-176.7)
Male	80	81.3	98.4	(78.1-122.5)	Ovary				
Female	95	92.4	102.8	(83.2-125.7)	Female	27	23.5	114.7	(75.6-166.9)
Esophagus					Pancreas				
Male	12	12.6	95.0	(49.0-165.9)	Male	13	15.1	86.2	(45.8-147.3)
Female	12	4.5	266.3	(137.5-465.3)	Female	17	19.1	88.9	(51.7-142.3)
Hodgkin Lymphoma					Prostate				

Male	8	5.1	155.9	(67.1-307.3)	Male	178	208.4	85.4	(73.3-98.9)
Female	6	4.7	128.9	(47.1-280.7)					
Kidney & Renal Pelvis					Stomach				
Male	27	21.1	127.8	(84.2-186.0)	Male	14	14.0	100.3	(54.8-168.3)
Female	5	15.7	31.9	(10.3-74.5)	Female	10	9.9	100.5	(48.1-184.9)
Larynx					Testis				
Male	7	9.4	74.7	(29.9-153.8)	Male	5	9.6	52.1	(16.8-121.6)
Female	4	2.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	13	17.0	76.4	(40.6-130.6)	Male	2	5.6	nc	(nc-nc)
Female	13	16.0	81.2	(43.2-138.8)	Female	10	19.6	51.1	(24.5-93.9)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	14	9.8	142.4	(77.8-239.0)					
Female	3	4.4	nc	(nc-nc)	Female	62	44.0	140.9	(108.1-180.7)
Lung and Bronchus					All Sites / Types				
Male	101	101.9	99.1	(80.7-120.4)	Male	642	706.4	90.9	(84.0-98.2)
Female	105	100.3	104.6	(85.6-126.7)	Female	739	756.0	97.8	(90.8-105.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

139  
Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)

Brain and Other Nervous System						Multiple Myeloma				
	Male	1	0.1	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.0	nc (nc-nc)
Breast						Non-Hodgkin Lymphoma				
	Male	0	0.0	nc	(nc-nc)		Male	1	0.3	nc (nc-nc)
	Female	1	1.5	nc	(nc-nc)		Female	0	0.2	nc (nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
							Male	0	0.2	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Colon / Rectum						Ovary				
	Male	0	0.9	nc	(nc-nc)					
	Female	0	0.6	nc	(nc-nc)		Female	0	0.2	nc (nc-nc)
Esophagus						Pancreas				
	Male	0	0.1	nc	(nc-nc)		Male	0	0.2	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.0	nc	(nc-nc)		Male	1	2.4	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	0	0.2	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Larynx						Testis				
	Male	0	0.1	nc	(nc-nc)		Male	0	0.0	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.2	nc	(nc-nc)		Male	0	0.0	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.1	nc	(nc-nc)					



Female	0	0.0	nc	(nc-nc)
Lung and Bronchus				
Male	0	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)

Female	0	0.3	nc	(nc-nc)
All Sites / Types				
Male	6	7.5	79.7	(29.1-173.6)
Female	2	4.8	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

140  
Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	0	1.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Esophagus				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Ovary				
Female	0	0.3	nc	(nc-nc)
Pancreas				

Hodgkin Lymphoma	Male	0	0.2	nc	(nc-nc)	Prostate	Male	0	0.3	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	1	0.2	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	0.1	nc	(nc-nc)	Stomach	Male	2	3.8	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Larynx	Male	0	0.4	nc	(nc-nc)	Testis	Male	0	0.1	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Leukemia	Male	0	0.2	nc	(nc-nc)	Thyroid	Male	0	0.1	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	2	0.3	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Male	0	0.1	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Lung and Bronchus	Male	0	0.2	nc	(nc-nc)	All Sites / Types	Female	1	0.6	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)		Male	10	12.3	81.5	(39.0-149.9)
	Male	3	1.8	nc	(nc-nc)		Female	9	9.3	96.8	(44.2-183.8)
	Female	0	1.2	nc	(nc-nc)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	25	22.4	111.4	(72.1-164.4)		Male	19	11.7	163.1	(98.1-254.7)
Female	12	8.7	138.3	(71.4-241.6)		Female	21	9.6	219.8	(136.0-336.1)
Brain and Other Nervous System						Multiple Myeloma				
Male	2	4.4	nc	(nc-nc)		Male	1	3.2	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)		Female	1	2.7	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.7	nc	(nc-nc)		Male	9	11.4	79.2	(36.1-150.3)
Female	103	94.2	109.4	(89.3-132.6)		Female	10	10.7	93.2	(44.6-171.5)
Cervix Uteri						Oral Cavity & Pharynx				
Female	2	4.2	nc	(nc-nc)		Male	4	9.1	nc	(nc-nc)
Colon / Rectum						Female	4	4.5	nc	(nc-nc)
Male	41	34.9	117.5	(84.3-159.4)		Ovary				
Female	29	35.1	82.6	(55.3-118.7)		Female	11	9.5	115.6	(57.6-206.8)
Esophagus						Pancreas				
Male	7	5.7	123.4	(49.4-254.3)		Male	4	6.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)		Female	5	7.3	68.7	(22.2-160.4)
Hodgkin Lymphoma						Prostate				
Male	2	1.7	nc	(nc-nc)		Male	98	96.2	101.9	(82.7-124.2)
Female	3	1.5	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	2	5.9	nc	(nc-nc)
Male	12	9.4	128.1	(66.1-223.8)		Female	2	3.7	nc	(nc-nc)
Female	7	6.3	111.7	(44.8-230.2)		Testis				
Larynx						Male	2	2.8	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)		Thyroid				
Female	2	1.1	nc	(nc-nc)		Male	2	2.2	nc	(nc-nc)
Leukemia										
Male	10	6.9	144.2	(69.0-265.1)						

Female	1	6.0	nc	(nc-nc)	Female	8	7.0	114.0	(49.1-224.6)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	4.3	nc	(nc-nc)					
Female	2	1.7	nc	(nc-nc)	Female	18	18.8	95.9	(56.8-151.6)
Lung and Bronchus					All Sites / Types				
Male	26	44.9	57.9	(37.8-84.9)	Male	285	308.0	92.5	(82.1-103.9)
Female	32	40.2	79.6	(54.4-112.4)	Female	297	299.8	99.1	(88.1-111.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

142  
Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	2.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	5	7.7	64.9	(20.9-151.4)	Female	1	0.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.4	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
					Female	0	0.4	nc	(nc-nc)
Colon / Rectum					Ovary				

Esophagus	Male	4	3.2	nc	(nc-nc)	Pancreas				
	Female	9	2.7	330.2	(150.7-626.9)		Female	3	0.8	nc (nc-nc)
Hodgkin Lymphoma	Male	2	0.5	nc	(nc-nc)	Prostate	Male	0	0.6	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	1	0.6	nc (nc-nc)
Kidney & Renal Pelvis	Male	0	0.2	nc	(nc-nc)	Stomach	Male	11	9.1	121.5 (60.6-217.4)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.3	nc (nc-nc)
Larynx	Male	1	0.9	nc	(nc-nc)	Testis	Male	0	0.3	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.6	nc (nc-nc)
Leukemia	Male	3	0.6	nc	(nc-nc)	Thyroid	Male	1	0.2	nc (nc-nc)
	Female	1	0.5	nc	(nc-nc)		Female	0	0.6	nc (nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.4	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
	Female	0	0.1	nc	(nc-nc)		Female	2	1.5	nc (nc-nc)
Lung and Bronchus	Male	1	4.2	nc	(nc-nc)	All Sites / Types	Male	34	28.8	118.0 (81.7-164.8)
	Female	3	3.2	nc	(nc-nc)		Female	30	24.2	123.7 (83.5-176.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	11	12.7	86.4	(43.1-154.5)	Male	2	6.4	nc	(nc-nc)
Female	6	4.7	126.6	(46.2-275.6)	Female	3	5.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	2.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	6	6.3	95.4	(34.8-207.6)
Female	47	48.9	96.2	(70.6-127.9)	Female	6	5.9	102.1	(37.3-222.2)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	2.2	nc	(nc-nc)	Male	6	4.7	126.3	(46.1-275.0)
					Female	5	2.4	209.5	(67.5-488.9)
Colon / Rectum					Ovary				
Male	24	19.6	122.3	(78.3-182.0)					
Female	14	18.9	74.2	(40.5-124.5)	Female	7	5.0	140.6	(56.3-289.8)
Esophagus					Pancreas				
Male	5	3.1	161.4	(52.0-376.6)	Male	2	3.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	5	4.0	126.3	(40.7-294.7)
Hodgkin Lymphoma					Prostate				
Male	4	1.0	nc	(nc-nc)	Male	48	53.4	89.9	(66.3-119.3)
Female	0	0.9	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	1	5.0	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	3.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
Larynx					Testis				
Male	4	2.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)

Leukemia	Female	1	0.6	nc	(nc-nc)
	Male	3	3.8	nc	(nc-nc)
	Female	4	3.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	5	2.3	214.5	(69.1-500.5)
	Female	0	0.9	nc	(nc-nc)
Lung and Bronchus	Male	28	25.4	110.2	(73.2-159.2)
	Female	29	22.6	128.6	(86.1-184.6)

#### Thyroid

Male	0	1.2	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)

#### Uteri Corpus and Uterus, NOS

Female	10	9.8	101.7	(48.7-187.1)
--------	----	-----	-------	--------------

#### All Sites / Types

Male	167	171.4	97.4	(83.2-113.4)
Female	160	159.9	100.0	(85.1-116.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

144  
Holden

#### Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	14	18.3	76.5	(41.8-128.4)
Female	3	6.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	5	3.5	143.2	(46.1-334.1)
Female	5	2.9	170.0	(54.8-396.7)
Breast				
Male	0	0.6	nc	(nc-nc)
Female	71	70.9	100.1	(78.2-126.3)
Cervix Uteri				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	7	9.3	75.1	(30.1-154.7)
Female	7	7.2	96.8	(38.8-199.4)
Multiple Myeloma				
Male	2	2.6	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	7	9.2	76.3	(30.6-157.3)
Female	7	8.2	85.3	(34.2-175.7)
Oral Cavity & Pharynx				

Colon / Rectum	Female	0	3.2	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
	Male	22	28.3	77.7	(48.7-117.7)	Female	3	3.4	nc	(nc-nc)
	Female	19	27.0	70.3	(42.3-109.8)	Ovary				
Esophagus	Male	2	4.5	nc	(nc-nc)		Female	11	7.2	153.2 (76.4-274.1)
	Female	0	1.3	nc	(nc-nc)		Male	3	5.3	nc (nc-nc)
	Male	1	1.4	nc	(nc-nc)	Pancreas	Female	4	5.6	nc (nc-nc)
Hodgkin Lymphoma	Female	2	1.2	nc	(nc-nc)		Male	59	75.4	78.3 (59.6-101.0)
	Male	2	7.4	nc	(nc-nc)		Female	1	4.8	nc (nc-nc)
	Female	3	4.7	nc	(nc-nc)	Prostate	Male	1	2.8	nc (nc-nc)
Kidney & Renal Pelvis	Male	2	7.4	nc	(nc-nc)		Female	2	2.2	nc (nc-nc)
	Female	0	0.8	nc	(nc-nc)		Male	2	1.7	nc (nc-nc)
	Male	7	5.6	125.2	(50.2-258.0)	Stomach	Female	7	5.4	130.1 (52.1-268.0)
Larynx	Female	4	4.6	nc	(nc-nc)		Male	185	245.9	75.2 (64.8-86.9)
	Male	3	3.4	nc	(nc-nc)		Female	198	227.3	87.1 (75.4-100.1)
	Female	0	0.8	nc	(nc-nc)	Testis				
Leukemia	Male	7	5.6	125.2	(50.2-258.0)		Male	2	1.7	nc (nc-nc)
	Female	4	4.6	nc	(nc-nc)		Female	7	5.4	130.1 (52.1-268.0)
	Male	7	5.6	125.2	(50.2-258.0)	Thyroid				
Liver and Intrahepatic Bile Ducts	Female	4	4.6	nc	(nc-nc)		Male	2	1.7	nc (nc-nc)
	Male	4	4.6	nc	(nc-nc)		Female	7	5.4	130.1 (52.1-268.0)
	Female	0	0.8	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
Lung and Bronchus	Male	4	4.6	nc	(nc-nc)		Female	15	13.9	107.9 (60.4-178.0)
	Female	0	0.8	nc	(nc-nc)					
	Male	26	35.9	72.4	(47.3-106.1)	All Sites / Types	Male	185	245.9	75.2 (64.8-86.9)
Lung and Bronchus	Female	20	30.4	65.7	(40.1-101.4)		Female	198	227.3	87.1 (75.4-100.1)
	Male	26	35.9	72.4	(47.3-106.1)					
	Female	20	30.4	65.7	(40.1-101.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;



- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

145

# Holland

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	2.2	279.1	(101.9-607.4)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.5	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	5	8.2	61.1	(19.7-142.6)	Female	1	0.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Colon / Rectum					Female	0	0.4	nc	(nc-nc)
Male	9	3.4	265.5	(121.1-504.0)	Ovary				
Female	6	2.5	243.1	(88.8-529.1)	Female	2	0.8	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.2	nc	(nc-nc)	Male	8	9.1	87.7	(37.8-172.8)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	2	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)

Larynx	Female	1	0.5	nc	(nc-nc)	Testis	Female	0	0.3	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)		Male	1	0.4	nc	(nc-nc)
Leukemia	Female	0	0.1	nc	(nc-nc)	Thyroid					
	Male	3	0.7	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.4	nc	(nc-nc)						
	Female	0	0.1	nc	(nc-nc)		Female	3	1.6	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	4	4.3	nc	(nc-nc)		Male	36	30.3	118.7	(83.1-164.3)
	Female	5	3.1	162.5	(52.4-379.2)		Female	25	24.5	102.1	(66.1-150.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

146  
Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	14	11.5	121.3	(66.3-203.6)	Male	10	6.9	144.3	(69.1-265.4)
Female	5	4.0	123.7	(39.9-288.7)	Female	7	5.7	123.2	(49.4-253.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	2.8	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Male	1	0.4	nc	(nc-nc)
Female	75	53.7	139.5	(109.7-174.9)
Cervix Uteri				
Female	4	2.7	nc	(nc-nc)
Colon / Rectum				
Male	19	18.4	103.1	(62.0-161.0)
Female	12	15.7	76.5	(39.5-133.7)
Esophagus				
Male	4	3.2	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	5	5.5	91.3	(29.4-213.1)
Female	2	3.3	nc	(nc-nc)
Larynx				
Male	3	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	5	4.0	125.7	(40.5-293.4)
Female	2	3.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	4	2.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Lung and Bronchus				
Male	17	23.9	71.0	(41.4-113.7)
Female	18	19.9	90.3	(53.5-142.7)

Male	6	6.6	91.0	(33.2-198.1)
Female	7	5.4	129.0	(51.7-265.8)
Oral Cavity & Pharynx				
Male	5	5.6	89.6	(28.9-209.1)
Female	2	2.4	nc	(nc-nc)
Ovary				
Female	2	5.3	nc	(nc-nc)
Pancreas				
Male	3	3.5	nc	(nc-nc)
Female	5	3.2	156.2	(50.4-364.6)
Prostate				
Male	54	53.6	100.8	(75.7-131.6)
Stomach				
Male	3	3.1	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)
Testis				
Male	5	2.1	237.7	(76.6-554.6)
Thyroid				
Male	0	1.5	nc	(nc-nc)
Female	6	4.8	125.2	(45.7-272.6)
Uteri Corpus and Uterus, NOS				
Female	12	10.5	114.1	(58.9-199.2)
All Sites / Types				
Male	173	171.1	101.1	(86.6-117.4)
Female	182	158.1	115.1	(99.0-133.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

147  
Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	43	42.3	101.6	(73.5-136.9)	Male	19	20.1	94.5	(56.9-147.6)
Female	11	17.5	62.9	(31.4-112.6)	Female	22	17.5	126.0	(78.9-190.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	7.8	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
Female	2	7.4	nc	(nc-nc)	Female	1	5.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)	Male	17	20.4	83.5	(48.6-133.7)
Female	147	162.9	90.2	(76.2-106.1)	Female	22	21.1	104.3	(65.3-157.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	13	7.3	177.2	(94.3-303.1)	Male	25	14.5	172.4	(111.5-254.5)
Colon / Rectum					Female	9	8.3	109.0	(49.7-206.9)
Male	78	64.4	121.1	(95.7-151.2)	Ovary				
Female	63	73.4	85.8	(66.0-109.8)	Female	16	17.1	93.3	(53.3-151.5)
Esophagus					Pancreas				
Male	10	9.7	103.2	(49.4-189.7)	Male	13	11.9	109.4	(58.2-187.1)
Female	3	3.6	nc	(nc-nc)	Female	18	15.3	117.8	(69.8-186.1)
Hodgkin Lymphoma					Prostate				
Male	2	3.3	nc	(nc-nc)	Male	133	161.4	82.4	(69.0-97.6)
Female	0	3.2	nc	(nc-nc)					

Kidney & Renal Pelvis					Stomach				
Male	11	15.7	70.2	(35.0-125.6)	Male	15	11.0	135.8	(76.0-224.0)
Female	11	11.7	94.1	(46.9-168.3)	Female	11	8.0	137.2	(68.4-245.4)
Larynx					Testis				
Male	8	7.1	113.1	(48.7-223.0)	Male	6	5.5	109.4	(39.9-238.0)
Female	2	2.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	16	13.0	123.2	(70.4-200.1)	Male	4	3.6	nc	(nc-nc)
Female	8	12.3	64.8	(27.9-127.8)	Female	8	12.5	63.8	(27.5-125.7)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	6	7.3	82.5	(30.1-179.5)					
Female	2	3.4	nc	(nc-nc)	Female	41	31.8	128.9	(92.5-174.9)
Lung and Bronchus					All Sites / Types				
Male	96	80.7	119.0	(96.4-145.3)	Male	546	543.5	100.5	(92.2-109.3)
Female	76	76.3	99.6	(78.5-124.7)	Female	534	562.3	95.0	(87.1-103.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

148  
Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	6.7	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)

Breast	Female	3	1.1	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
Cervix Uteri	Female	28	25.9	108.3	(71.9-156.5)
Colon / Rectum	Female	1	1.2	nc	(nc-nc)
	Male	6	10.3	58.0	(21.2-126.2)
Esophagus	Female	5	10.4	48.2	(15.5-112.4)
	Male	1	1.6	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.5	nc	(nc-nc)
	Male	0	0.5	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	2.6	nc	(nc-nc)
	Female	7	1.8	393.9	(157.8-811.6)
Larynx	Male	2	1.2	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)
Leukemia	Male	2	2.1	nc	(nc-nc)
	Female	0	1.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	2	1.2	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)
Lung and Bronchus					

Non-Hodgkin Lymphoma	Female	3	0.8	nc	(nc-nc)
	Male	1	3.3	nc	(nc-nc)
Oral Cavity & Pharynx	Female	3	3.1	nc	(nc-nc)
	Male	0	2.5	nc	(nc-nc)
Ovary	Female	1	1.2	nc	(nc-nc)
Pancreas	Female	1	2.6	nc	(nc-nc)
	Male	5	1.9	260.9	(84.1-608.9)
Prostate	Female	3	2.2	nc	(nc-nc)
	Male	20	26.0	77.1	(47.0-119.0)
Stomach	Male	0	1.8	nc	(nc-nc)
	Female	0	1.1	nc	(nc-nc)
Testis	Male	2	0.9	nc	(nc-nc)
Thyroid	Male	0	0.6	nc	(nc-nc)
	Female	3	2.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					
	Female	3	5.0	nc	(nc-nc)
All Sites / Types					

Male	13	12.9	100.4	(53.4-171.7)
Female	8	11.4	70.0	(30.1-137.9)

Male	70	87.8	79.8	(62.2-100.8)
Female	78	84.9	91.8	(72.6-114.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

149  
Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	8.5	59.0	(19.0-137.8)	Male	8	5.5	145.5	(62.7-286.8)
Female	2	3.1	nc	(nc-nc)	Female	6	4.7	127.6	(46.6-277.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	45	42.1	106.9	(78.0-143.0)	Female	4	4.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	2.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Colon / Rectum					Female	2	1.8	nc	(nc-nc)
Male	10	13.6	73.4	(35.1-135.0)	Ovary				
Female	12	12.4	97.1	(50.1-169.7)	Female	8	4.1	193.5	(83.3-381.3)
Esophagus					Pancreas				
Male	2	2.3	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	5	2.5	200.7	(64.7-468.3)

Hodgkin Lymphoma						Prostate				
Male	0	1.0	nc	(nc-nc)		Male	37	37.3	99.2	(69.9-136.8)
Female	1	0.9	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	3	4.2	nc	(nc-nc)		Male	3	2.3	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)		Female	0	1.3	nc	(nc-nc)
Larynx						Testis				
Male	1	1.8	nc	(nc-nc)		Male	1	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)						
Leukemia						Thyroid				
Male	7	3.2	218.3	(87.4-449.8)		Male	3	1.3	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)		Female	4	4.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	2	2.0	nc	(nc-nc)						
Female	1	0.6	nc	(nc-nc)		Female	7	7.8	89.9	(36.0-185.2)
Lung and Bronchus						All Sites / Types				
Male	17	17.2	98.7	(57.4-158.0)		Male	120	126.5	94.9	(78.7-113.5)
Female	15	14.8	101.5	(56.8-167.4)		Female	130	124.2	104.7	(87.5-124.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

150  
Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	2.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)



Female	0	0.9	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	5	11.9	41.9	(13.5-97.7)
Cervix Uteri				
Female	1	0.7	nc	(nc-nc)
Colon / Rectum				
Male	3	4.4	nc	(nc-nc)
Female	5	3.4	145.8	(47.0-340.1)
Esophagus				
Male	3	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	1.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Larynx				
Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	2	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				

Female	1	1.4	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.6	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Ovary				
Female	2	1.2	nc	(nc-nc)
Pancreas				
Male	0	0.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)
Prostate				
Male	15	12.2	123.1	(68.8-203.0)
Stomach				
Male	0	0.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)
Testis				
Male	1	0.6	nc	(nc-nc)
Thyroid				
Male	0	0.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				

Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	4	5.6	nc	(nc-nc)	Male	40	40.5	98.9	(70.6-134.6)
Female	4	4.2	nc	(nc-nc)	Female	29	35.1	82.6	(55.3-118.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

151  
Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	15	17.3	86.8	(48.5-143.1)	Male	7	9.5	74.0	(29.6-152.4)
Female	7	6.6	105.9	(42.4-218.2)	Female	7	7.8	90.2	(36.1-185.8)
Brain and Other Nervous System					Multiple Myeloma				
Male	3	3.7	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)	Male	5	9.2	54.5	(17.6-127.1)
Female	62	72.5	85.6	(65.6-109.7)	Female	4	8.4	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	5	3.5	142.5	(45.9-332.6)	Male	6	7.2	83.6	(30.5-182.1)
					Female	5	3.5	144.6	(46.6-337.5)
Colon / Rectum					Ovary				
Male	33	27.0	122.2	(84.1-171.6)					
Female	21	26.5	79.3	(49.1-121.2)	Female	5	7.3	68.2	(22.0-159.1)

Esophagus						Pancreas				
Male	6	4.4	136.6	(49.9-297.3)		Male	3	5.1	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)		Female	8	5.5	145.6	(62.7-286.9)
Hodgkin Lymphoma						Prostate				
Male	1	1.7	nc	(nc-nc)		Male	74	74.3	99.5	(78.2-125.0)
Female	1	1.4	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	6	7.4	81.5	(29.8-177.5)		Male	2	4.6	nc	(nc-nc)
Female	3	4.9	nc	(nc-nc)		Female	2	2.8	nc	(nc-nc)
Larynx						Testis				
Male	5	3.3	151.3	(48.7-353.0)		Male	4	3.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)						
Leukemia						Thyroid				
Male	10	5.6	179.8	(86.1-330.6)		Male	1	2.0	nc	(nc-nc)
Female	6	4.6	129.1	(47.1-281.0)		Female	5	6.1	81.7	(26.3-190.8)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	2	3.4	nc	(nc-nc)						
Female	1	1.3	nc	(nc-nc)		Female	11	14.3	76.8	(38.3-137.4)
Lung and Bronchus						All Sites / Types				
Male	47	34.7	135.6	(99.6-180.3)		Male	244	241.6	101.0	(88.7-114.5)
Female	33	31.4	105.2	(72.4-147.8)		Female	207	231.9	89.3	(77.5-102.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	18	11.3	159.0	(94.2-251.3)
Female	8	3.9	203.0	(87.4-400.0)
Brain and Other Nervous System				
Male	1	2.3	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	59	46.8	126.1	(95.9-162.6)
Cervix Uteri				
Female	0	2.3	nc	(nc-nc)
Colon / Rectum				
Male	22	17.7	124.3	(77.9-188.2)
Female	19	15.5	122.5	(73.7-191.3)
Esophagus				
Male	2	2.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	1.0	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	4.8	nc	(nc-nc)
Female	5	3.0	165.2	(53.3-385.6)
Larynx				
Male	5	2.2	230.7	(74.3-538.4)
Female	2	0.6	nc	(nc-nc)
Leukemia				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	11	6.1	179.4	(89.4-321.0)
Female	5	4.9	101.2	(32.6-236.2)
Multiple Myeloma				
Male	1	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	6.0	134.3	(57.8-264.6)
Female	7	5.1	136.8	(54.8-281.9)
Oral Cavity & Pharynx				
Male	9	4.7	189.9	(86.7-360.6)
Female	1	2.2	nc	(nc-nc)
Ovary				
Female	9	4.7	193.0	(88.1-366.4)
Pancreas				
Male	3	3.3	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)
Prostate				
Male	49	48.7	100.6	(74.4-133.0)
Stomach				
Male	2	3.0	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)
Testis				
Male	2	1.8	nc	(nc-nc)
Thyroid				

Male	6	3.6	167.8	(61.3-365.2)	Male	3	1.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	5	4.0	125.8	(40.5-293.6)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	2.2	nc	(nc-nc)					
Female	2	0.8	nc	(nc-nc)	Female	9	9.3	96.6	(44.1-183.4)
Lung and Bronchus					All Sites / Types				
Male	27	22.7	119.2	(78.5-173.4)	Male	186	157.6	118.0	(101.6-136.2)
Female	33	19.2	172.0	(118.4-241.5)	Female	181	144.2	125.5	(107.9-145.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

153 Huntington									
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	3	2.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	9	8.0	112.1	(51.1-212.7)	Female	1	0.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)

Colon / Rectum						Ovary				
Male	3	3.2	nc	(nc-nc)						
Female	0	2.7	nc	(nc-nc)		Female	0	0.8	nc	(nc-nc)
Esophagus						Pancreas				
Male	1	0.5	nc	(nc-nc)		Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)		Female	0	0.5	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	0	0.2	nc	(nc-nc)		Male	3	8.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	1	0.9	nc	(nc-nc)		Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Larynx						Testis				
Male	1	0.4	nc	(nc-nc)		Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)						
Leukemia						Thyroid				
Male	1	0.7	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)		Female	2	0.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	0.4	nc	(nc-nc)						
Female	0	0.1	nc	(nc-nc)		Female	1	1.6	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
Male	3	4.1	nc	(nc-nc)		Male	20	28.7	69.6	(42.5-107.5)
Female	5	3.2	157.0	(50.6-366.4)		Female	28	24.8	113.0	(75.0-163.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;